Related Experiment Video

Updated: Jun 5, 2026

Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates

Fekadu Fullas1, Michael T Padomek, Corey J Thieman

  • 1Pharmacy Department, St. Luke’s Regional Medical Center, 2720 Stone Park Boulevard, Sioux City, IA 51104, USA. fullasfx@stlukes.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|December 18, 2010
PubMed

Insights

Optimizing gentamicin dosing in neonates is crucial for effective treatment. Extended intervals of 4.5 mg/kg every 48 hours for premature infants and 3.5 mg/kg every 36 or 24 hours for older neonates achieve target peak concentrations.

Area of Science:

  • Neonatal Pharmacology
  • Antibiotic Dosing Optimization
  • Pediatric Infectious Diseases

Background:

  • Gentamicin is a critical antibiotic for treating neonatal infections.
  • Establishing optimal dosing regimens is essential to maximize efficacy and minimize toxicity in neonates.
  • Premature and full-term neonates exhibit unique pharmacokinetic profiles requiring tailored gentamicin administration.

Purpose of the Study:

  • To compare the efficacy of six extended-interval gentamicin dosing regimens in premature and full-term neonates.
  • To determine the optimal gentamicin dosage and interval for different gestational age groups.
  • To identify dosing strategies that achieve target peak gentamicin concentrations in neonates.

Main Methods:

  • Retrospective analysis of physician-ordered gentamicin dosing regimens in a neonatal intensive care unit.
  • Categorization of neonates by gestational age (GA): ≤29 weeks, 30-34 weeks, and ≥35 weeks.
  • Blood samples collected pre- and post-infusion of the third dose to determine trough and peak gentamicin levels.

Main Results:

  • Neonates (GA ≤29 weeks) achieved target peak concentrations with 4.5 mg/kg every 48 hours.
  • Neonates (GA 30-34 weeks) showed optimal peak concentrations with 3.5 mg/kg every 36 hours.
  • Neonates (GA ≥35 weeks) had the highest percentage of target peaks with 3.5 mg/kg every 24 hours.

Conclusions:

  • Gentamicin 3.5 mg/kg every 36 hours is recommended for neonates aged 30-34 weeks GA.
  • Gentamicin 3.5 mg/kg every 24 hours is suggested for neonates aged 35 weeks GA and older.
  • No significant differences in trough levels were observed across subgroups within each age group.
Abstract

More Related Videos

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...